Validation of nasal potential difference measurements in gut-corrected CF knockout mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 39, Issue 4, 2008, Pages 490-496

  Griesenbach, Uta ^a,b,c   Smith, Stephen N ^a,b   Farley, Raymond ^a,b   Singh, Charanjit ^a,b   Alton, Eric W F W ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UK Cystic Fibrosis Gene Therapy Consortium ^*

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CF mice; Cystic fibrosis; Gut corrected; Nasal potential difference

Indexed keywords

FATTY ACID BINDING PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AGE; ANIMAL EXPERIMENT; ARTICLE; BIOENERGY; CALCULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; ENTEROPATHY; FEMALE; GENE THERAPY; GENE TRANSFER; KNOCKOUT MOUSE; MALE; MOLECULAR THERAPY; MOUSE; NASAL POTENTIAL DIFFERENCE; NONHUMAN; POTENTIAL DIFFERENCE; POWER ANALYSIS; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; SAMPLE SIZE; SEX DIFFERENCE; WILD TYPE;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FATTY ACID-BINDING PROTEINS; FEMALE; INTESTINES; MALE; MEMBRANE POTENTIALS; MICE; MICE, KNOCKOUT; NASAL MUCOSA; PROMOTER REGIONS, GENETIC;

ANIMALIA; MUS;

EID: 53349173392     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0385OC     Document Type: Article

References (22)

1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-482.
2. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006;13:1061-1067.
3. Rubenstein RC. New pharmacological approaches for treatment of cystic fibrosis. In: Bush A, Alton EWFW, Davies JC, Griesenbach U, Jaffe A, editors. Progress in respiratory research: cystic fibrosis in the 21st century. London: Karger; 2006. p. 212-220.
4. Dorin JR. Animal models. In: Bush A, Alton EW, Davies JC, Griesenbach U, Jaffe A, editors. Progress in respiratory research: cystic fibrosis in the 21st century. London: Karger; 2006. p. 84-92.
5. Grubb BR, Paradiso AM, Boucher RC. Anomalies in ion transport in cf mouse tracheal epithelium. Am J Physiol 1994;267:C293-C300.
6. Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN, Engelhardt JF, Wilson JM, Johnson LG, Boucher RC. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994;371:802-806.
7. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH. An animal model for cystic fibrosis made by gene targeting. Science 1992;257:1083-1088.
8. Delaney SJ, Alton EW, Smith SN, Lunn DP, Farley R, Lovelock PK, Thomson SA, Hume DA, Lamb D, Porteous DJ, et al. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J 1996;15:955-963.
9. Colledge WH, Abella BS, Southern KW, Ratcliff R, Jiang C, Cheng SH, MacVinish LJ, Anderson JR, Cuthbert AW, Evans MJ. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat Genet 1995;10:445-452.
10. Grubb BR, Gabriel SE. Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Am J Physiol 1997;273:G258-G266.
11. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994;266:1705-1708.
12. Steagall WK, Elmer HL, Brady KG, Kelley TJ. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 2000;22:45-50.
13. Parsons DW, Hopkins PJ, Bourne AJ, Boucher RC, Martin AJ. Airway gene transfer in mouse nasal-airways: importance of identification of epithelial type for assessment of gene transfer. Gene Ther 2000;7:1810-1815.
14. Smith SN, Middleton PG, Chadwick S, Jaffe A, Bush KA, Rolleston S, Farley R, Delaney SJ, Wainwright B, Geddes DM, et al. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 1999;20:129-134.
15. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455.
16. MacVinish LJ, Goddard C, Colledge WH, Higgins CF, Evans MJ, Cuthbert AW. Normalization of ion transport in murine cystic fibrosis nasal epithelium using gene transfer. Am J Physiol 1997;273:C734-C740.
17. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-25.
18. Dorin JR, Farley R, Webb S, Smith SN, Farini E, Delaney SJ, Wainwright BJ, Alton EW, Porteous DJ. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther 1996;3:797-801.
19. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003;361:1671-1676.
20. Alton EW, Middleton PG, Caplen NJ, Smith SN, Steel DM, Munkonge FM, Jeffery PK, Geddes DM, Hart SL, Williamson R, et al. Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 1993;5:135-142.
21. xAlton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999;353:947-954.
22. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004;15:1255-1269.